VP, CFO & Treasurer of Targacept Inc. (TRGT, Financial) Alan A Musso sells 4,500 shares of TRGT on 08/14/2009 at an average price of $13.51 a share.
TARGACEPT INC is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept\'s product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer\'s disease cognitive dysfunction in schizophrenia pain and depression as well as multiple preclinical programs. Targacept also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. Targacept inc. has a market cap of $336.78 million; its shares were traded at around $13.49 with and P/S ratio of 16.77.
TRGT is in the portfolios of Jean-Marie Eveillard of Arnhold & S. Bleichroeder Advisers, LLC.
Recent Trades of Targacept Inc. by CEO:
Recent Trades of Targacept Inc. by CFO:
Recent Trades of Targacept Inc. by Directors and Officers:
TARGACEPT INC is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept\'s product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer\'s disease cognitive dysfunction in schizophrenia pain and depression as well as multiple preclinical programs. Targacept also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. Targacept inc. has a market cap of $336.78 million; its shares were traded at around $13.49 with and P/S ratio of 16.77.
TRGT is in the portfolios of Jean-Marie Eveillard of Arnhold & S. Bleichroeder Advisers, LLC.
Recent Trades of Targacept Inc. by CEO:
- Sell: President and CEO J Donald Debethizy sold 5,700 shares of TRGT stock on 08/07/2009 at the average price of $12.03; the price of the stock has increased by 12.14% since.
- Sell: President and CEO J Donald Debethizy sold 5,700 more shares of TRGT stock on 07/29/2009 at the average price of $11.27; the price of the stock has increased by 19.7% since.
- Sell: President and CEO J Donald Debethizy sold 2,600 more shares of TRGT stock on 07/28/2009 at the average price of $11.01; the price of the stock has increased by 22.52% since.
Recent Trades of Targacept Inc. by CFO:
- Sell: VP, CFO & Treasurer Alan A Musso sold 5,700 shares of TRGT stock on 08/07/2009 at the average price of $12.03; the price of the stock has increased by 12.14% since.
- Sell: VP, CFO & Treasurer Alan A Musso sold 5,263 more shares of TRGT stock on 07/29/2009 at the average price of $11.29; the price of the stock has increased by 19.49% since.
- Sell: VP, CFO & Treasurer Alan A Musso sold 3,037 more shares of TRGT stock on 07/28/2009 at the average price of $11.02; the price of the stock has increased by 22.41% since.
Recent Trades of Targacept Inc. by Directors and Officers:
- Buy: 10% Owner Partners L P/il Bvf bought 25,700 shares of TRGT stock on 07/13/2009 at the average price of $3.06; the price of the stock has increased by 340.85% since.
- Buy: Director Julia R Brown bought 7,500 shares of TRGT stock on 03/17/2009 at the average price of $3.03; the price of the stock has increased by 345.21% since.
- Sell: VP - Drug Discovery and Dev. William S Caldwell sold 6,780 shares of TRGT stock on 08/11/2009 at the average price of $12.69; the price of the stock has increased by 6.3% since.
- Sell: VP - Bus. & Commercial Dev. Jeffrey P Brennan sold 15,000 shares of TRGT stock on 08/10/2009 at the average price of $12.63; the price of the stock has increased by 6.81% since.
- Sell: VP - Drug Discovery and Dev. William S Caldwell sold 771 shares of TRGT stock on 08/07/2009 at the average price of $12.01; the price of the stock has increased by 12.32% since.
